Skip to main content
  • Home
  • Incretin Management in Type 2 Diabetes

Incretin Management in Type 2 Diabetes

Topic:
  • Prevention

Available Credit:

  • 1.00 EBAC

Course Published On:

Course Expiry Date:

Overview

In this educational hub ‘Incretin Management in Type 2 Diabetes’ the faculty present the importance of screening and early intensification for better glycaemic control and improved vascular and mortality outcomes in type 2 diabetes.

In this series of CME accredited videos and downloadable summaries, leading global experts will guide you through how the incretin system works, what happens to it in type 2 diabetes and how to optimise the use of incretin-based agents for better patient outcomes.

Disclosure

In compliance with EBAC / EACCME guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.



The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.


This programme is supported by an unrestricted educational grant by Novo Nordisk A/S. The scientific programme has not been influenced in any way by the sponsors.

Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
 

The session of ‘Incretin Management in Type 2 Diabetes’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.
 

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
 

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

Target Audience

This programme is intended to educate:

  • Primary care physicians (PCPs)/ General Practitioners (GPs)
  • Endocrinologists
  • Diabetologists
  • Nurses

Learning Objectives

The overall programme, ‘Incretin Management in Type 2 Diabetes’’, endeavours to best address the following learning objectives:

  • Recall the components of the ‘ominous octet’ & how they contribute to T2DM development
  • Identify underlying facets of clinical inertia in T2DM care
  • Describe how early adoption of intensive glycaemic control leads to better outcomes in T2DM
  • Recall efficacy & the mode of action of various incretin-based treatments
  • Adopt an early, intensive glucose-lowering strategy in appropriate individuals 
  • Select appropriate incretin treatment & dosing regimens according to patient profiles 
  • Identify individuals likely to gain cardiovascular benefit from GLP-1RAs 
  • Select appropriate actions following adverse events from incretin-based treatments
Register now Log in

Module

Title

Duration

Speakers

Session 1 Diabetes pathophysiology and the 'ominous octet' 10 minutes Silvio Inzucchi ()
Session 2 The incretin system & incretin-targeting agents 10 minutes Silvio Inzucchi ()
Session 3 Therapeutic inertia in T2DM 10 minutes Kamlesh Khunti ()
Session 4 Early glycaemic control in T2DM 10 minutes Kamlesh Khunti ()
Session 5 The use of GLP-1 RAs in T2DM 10 minutes Sarah Davies ()
Session 6 Incretin-based drugs: What does the data say? 10 minutes Sarah Davies ()
Session 7 Incretin-based drugs: Mode of action/delivery & dosing schedule 10 minutes Su Down ()
Session 8 Appropriate prescribing practices 10 minutes Su Down ()
Session 9 Beyond glycaemic control: Cardiovascular benefits 10 minutes Mikhail Kosiborod ()
Session 10 Beyond glycaemic control: Weight control 10 minutes Mikhail Kosiborod ()
Session 1.

Diabetes pathophysiology and the 'ominous octet'

Duration: 10 minutes

Speakers: Silvio Inzucchi ()

Session 2.

The incretin system & incretin-targeting agents

Duration: 10 minutes

Speakers: Silvio Inzucchi ()

Session 3.

Therapeutic inertia in T2DM

Duration: 10 minutes

Speakers: Kamlesh Khunti ()

Session 4.

Early glycaemic control in T2DM

Duration: 10 minutes

Speakers: Kamlesh Khunti ()

Session 5.

The use of GLP-1 RAs in T2DM

Duration: 10 minutes

Speakers: Sarah Davies ()

Session 6.

Incretin-based drugs: What does the data say?

Duration: 10 minutes

Speakers: Sarah Davies ()

Session 7.

Incretin-based drugs: Mode of action/delivery & dosing schedule

Duration: 10 minutes

Speakers: Su Down ()

Session 8.

Appropriate prescribing practices

Duration: 10 minutes

Speakers: Su Down ()

Session 9.

Beyond glycaemic control: Cardiovascular benefits

Duration: 10 minutes

Speakers: Mikhail Kosiborod ()

Session 10.

Beyond glycaemic control: Weight control

Duration: 10 minutes

Speakers: Mikhail Kosiborod ()

Course Director

Mikhail Kosiborod

Cardiometabolic Center of Excellence , Saint Luke’s Mid America Heart Institute

Dr Kosiborod is an internationally recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, and quality care and outcomes. He is a cardiologist, Vice President of Research at Saint Luke's Health System, Director of Cardiometabolic Research

View full profile

Speaker

Silvio Inzucchi

Yale University, School of Medicine

Dr Inzucchi is a Professor of Medicine at the Yale University School of Medicine in New Haven, where he serves as Clinical Chief of the Section of Endocrinology, Medical Director of the Yale Diabetes Center, and Program Director of the Endocrinology & Metabolism Fellowship. 

View full profile

Speaker

Kamlesh Khunti

University of Leicester

Prof Khunti is the Professor of Primary Care Diabetes and Vascular Medicine at the University of Leicester and Co-Director of the Leicester Diabetes Centre.  His work has greatly influenced guidelines on the screening and management of people with diabetes.

View full profile

Speaker

Sarah Davies

Woodlands Medical Centre

Dr Davies graduated from the University of Wales College of Medicine in 2003, initially pursuing a career in medicine, especially diabetes and endocrinology. She then made the move to General Practice and continued her interest in diabetes, completing the Cardiff Postgraduate diploma in diabetes.

View full profile

Speaker

Su Down

Somerset NHS Foundation Trust

Su Down is a Nurse Consultant in Diabetes and is the Clinical Lead for the Intermediate Diabetes community service in Somerset.  Her Diabetes nursing career started in 1989, when she set up the diabetes specialist nursing service in Yeovil District Hospital.  Su took up the role of Nurse Consulta

View full profile

1.00 European Board for Accreditation in Cardiology (EBAC)

Related Courses

Meeting Real-world Challenges in Hypercholesterolaemia Management: Insight from a Pan-European Crowdsourcing Activity
  • 1.00 European Board for Accreditation in Cardiology (EBAC)

Learning objectives

  • Discuss the current practice gaps in hypercholesterolaemia management
  • Recall best practice for assessing CV risk, defining LDL-C targets and offering patient education
  • Stratify patients by CV risk category
  • Select cholesterol-lowering therapies according to risk category and LDL-C target
See more
Intracoronary imaging for PCI: A practical approach to OCT
  • 1.00 EBAC

Learning objectives

  • Incorporate contemporary imaging for PCI in appropriate patients
  • Differentiate between modern imaging techniques based on clinical data
  • Recall best practices for image acquisition, interpretation and decision-making
  • Interpret image data and make clinical decisions generated from existing case study data
See more
Imaging vs angiography-led PCI: What does success look like?
  • 1.00 EBAC

Learning objectives

  • Incorporate contemporary imaging for PCI in appropriate patients
  • Differentiate between modern imaging techniques based on clinical data
  • Recall best practices for image acquisition, interpretation and decision-making
  • Interpret image data and make clinical decisions generated from existing case study data
See more
Imaging-based Procedure-planning with OCT: Application to Clinical Practice
  • 1.00 EBAC

Learning objectives

  • Incorporate contemporary imaging for PCI in appropriate patients
  • Differentiate between modern imaging techniques based on clinical data
  • Recall best practices for image acquisition, interpretation and decision-making
  • Interpret image data and make clinical decisions generated from existing case study data
See more
Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data.
  • Differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
  • Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF.
  • Assess the interrelationships linking diabetes, HF and CVD.
  • Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
  • Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more
Current and Emerging Data on SGLT2 Inhibitors in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data;
  • differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF);
  • apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF;
  • assess the interrelationships linking diabetes, HF and CVD;
  • interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF. Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
See more